Personalis, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Q2 2026: Total revenue $22.4M (+30% YoY); clinical revenue $2.6M (+442% YoY) on 10,384 tests (+199% YoY); pharma testing $16.8M (+51% YoY); cash position $212.7M. Medicare approvals secured for NeXT Personal in IO monitoring and neoadjuvant breast cancer. On July 20, 2026, Personalis announced agreement to be acquired by Tempus AI, Inc.; company will cease quarterly guidance and earnings calls.
Why this rating
Strong operational growth (clinical volume +199% YoY) and Medicare expansions are positive, but pending acquisition dominates; creates execution uncertainty and removes forward guidance. Material relative to $578M market cap but acquisition terms not disclosed.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.